Filana Therapeutics Inc (FLNA) Smart Money Holdings (13F, Q2 2026)

FLNA ranks #4915 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

FLNA is a disclosed holding of Two Sigma (Two Sigma Investments), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

87 institutions disclose a position in FLNA, but none treat it as a major bet — even Gmt Capital CORP, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Goldman Sachs Group Inc has added to its FLNA position for two straight quarters, increasing it by $730.5K to reach $795.9K today.

Marshall Wace, LLP has trimmed its FLNA position for two straight quarters, cutting it by $2.3M while still holding $1.9M.

FLNA reported a net loss of $77.9M over the trailing twelve months.

• Not yet profitable — net loss of $77.9M over the trailing twelve months
• Revenue grew 277.6% year over year
• Net income declined year over year, from -$72.8M to -$77.9M
• Operating cash flow was negative, using $32.3M in cash
• Current ratio of 2.23x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.59x equity — within a conventional range